This 1.5 hour online CME/CMLE multidisciplinary panel discussion will discuss how to apply the latest science and evidence as you navigate administrative challenges surrounding institutional policies and procedures. You will gain a deeper understanding that surrounds the complexity of PD-L1 testing based on the type of tumor, different antibody assays, and scoring systems. Additionally, you will learn about the practical application of MSI/MMR testing and the potentially emerging role of tumor mutational burden (TMB) when treating patients with checkpoint inhibitor therapy.
To claim CME credit for this course, please register at:
Your comment will be posted after it is approved.
Leave a Reply.
Sign up to receive updates: